<DOC>
	<DOCNO>NCT01759810</DOCNO>
	<brief_summary>Trial Hypothesis : Acute , progress lethal neurooncological process transfer chronic non-lethal , survival rate life quality improve control tumor cell ( TCs ) quantity target regulation effector function tumor stem cell ( TSCs ) . Brief Description : The first line therapy glioblastoma multiforme ( GBM ) involve allogeneic haploidentical hematopoietic stem cell ( HSCs ) , dendritic vaccine ( DV ) cytotoxic lymphocyte ( CTLs ) . TCs TSCs isolate GBM sample . Dendritic cell isolated peripheral blood mononuclear cell culture . Tumor sample provide tumor specific antigen prepare DV . CTLs obtain peripheral blood DV administration . HSCs harvest closely related donor granulocyte-colony-stimulating factor ( G-CSF ) administration . Allogeneic HSCs administer intrathecally 5 time every 2 week , day 1 , 14 , 28 , 42 , 56 . DV give 3 time every 2 week ( day 14 , 28 , 42 ) subcutaneously four point . CTLs administer every 2 week 3 month , 3 time every 1 month intrathecally . Six month therapy completion , efficiency evaluate cohort demonstrate efficiency continue therapy , cohort demonstrate efficiency transfer active comparator arm . Second line therapy involve DV recombinant protein , CTLs autologous HSC modify proteome . Autologous HSCs mobilize G-CSF . Carcinogenesis-free intracellular pathway signal transduction able respond target regulation therapeutic cell system specific property , detect TSCs use complete transcriptome profile gene expression , proteome mapping profiling protein , bioinformation mathematical analysis mathematical modeling protein profile . To find key oncospecific protein TSCs TCs , target TSCs regulation detect , well protein ligand able regulate reproductive proliferative property TSCs . Using data TCs TSCs proteins , cell preparation initiate adoptive immune response prepare : DV load recombinant protein analogous key tumor antigen , CTLs autologous proteome-modified HSCs . Autologous proteome-modified HSCs , DV CTLs administer first line therapy .</brief_summary>
	<brief_title>Proteome-based Personalized Immunotherapy Glioblastoma</brief_title>
	<detailed_description>The trial include 60 case unresectable recurrent glioblastoma multiforme ( GBM ) two line standard chemotherapy complete course radiotherapy . The first line therapy GBM involve allogeneic haploidentical hematopoietic stem cell ( HSCs ) , dendritic vaccine ( DV ) cytotoxic lymphocyte ( CTLs ) . HSCs use stimulate individualized adoptive immune response , affect tumor cell ( TCs ) toxically regulate tumor stem cell ( TSCs ) target order suppress reproductive proliferative potential . To obtain HSC donor receive 8 subcutaneous administration granulocyte colony-stimulating factor ( G-CSF ) 8-10 hour interval 4 day . The first three day single dose 2.5 mcg per 1 kg weight , last day dose double . The stem cell harvest day 5 . Red blood cell withdraw centrifuge . The content cell marker evaluate flow cytometry . The result assess cytoconcentrate enrichment removal mature cell plasma . The preparation store tube per 4 ml cryoprotector 10 % polyglucin solution . Stem cell proportion le 0.5x106 CD34+ , lymphocytes proportion le 0.5x109 per one administration . The sample brain tumor obtain stereotaxic/ endoscopic/ open biopsy patient include trial . The TCs TSCs immunochemically isolate GBM biopsy sample . One part tumor sample use standard histological , cytological immunochemical testing , tumor cell ( TCs ) tumor stem cell ( TSCs ) ( CD133+ ) isolate part . Dendritic cell isolated peripheral blood mononuclear cell culture . Tumor sample provide tumor specific antigen prepare DV . Preparation CTLs aim enhance cytotoxic effect tumor due great number circulate CTLs . CTLs isolate 100 ml peripheral blood 3 DV administration , dendritic cell ( DCs ) grown . Then , peripheral blood repeatedly take , lymphocytes isolate . The CTLs co-cultured DCs load tumor antigen ( first line therapy ) recombinant proteins identical key oncospecific protein ( second-line therapy ) several time expand number ( 108-109 ) . Their immunophenotype detect CTLs cryopreserved . The first stimulation CTLs DCs last 6-8 day , second last 2-4 day , next 2 day lymphocytes stimulate third fourth time . And receive lymphocyte stimulate IL-2 2 day . Six month first line therapy completion efficiency evaluate cohort demonstrate efficiency continue therapy , cohort demonstrate efficiency continue trial second line therapy . The second line therapy arm ( active comparator arm ) use DV recombinant protein identical key oncospecific protein , autologous CTLs autologous HSCs modify proteome . Autologous HSCs receive trial participant describe previously . Cell preparation HSC active comparator arm obtain cytoconcentrate autologous mononuclear cell peripheral blood mobilization specify experimental arm . Tumor specific antigen active comparator group provide tumor tissue patient . TCs TSCs well HSCs patient undergo complete transcriptome mapping gene expression profile ( CTMGEP ) proteome map protein profiling ( PMPP ) . Key ( 3 4 protein maximal normalized intensity ) oncospecific protein ( OSP ) determine accord proteome testing TCs , proteome profiling TSCs use databases protein-protein relation permit detection intracellular signal transduction pathway ( ISTP ) unaffected carcinogenesis capable regulation . Also , receptor membrane target affect signal pathway ( acceptor membrane protein ) detect , well proteins able activate ( protein ligands ) . CTMGEP TSCs confirms diagnose functional ISTP . Mathematical model CTMGEP comparison Affymetrix GeneChip Human genome U133A Array data reveals perturbagens able chemically induce HSCs modify proteome profile order provide secretion requisite protein ligands . The database analysis permit understanding change gene expression induce low-molecular agent micro RNA correspond change observe examined profile . If correspondence significant , suppose , agent similar agent initiate effect . If anticorrelation significant , agent suppose initiate opposite effect gene expression modification . The transcriptome HSCs modify co-culturing mononuclear cell perturbagens . Their biological efficiency evaluate vitro Homunculus bioreactor . Then preparation store describe previously . Individual DV prepare leukoconcentrate peripheral blood patient . The lymphocyte isolate , culture G-CSF interleukin-2 , condition tumor-specific antigen , TNF-Î± PGE2 48 hour load recombinant protein identical key tumor-specific antigen detect proteomic test TCs . Basic mechanism individual DV immune effect elaboration tumor toxic lymphocytes organism patient . CTLs obtain describe previously . The intervention describe appropriate section . Toxicity evaluate accord CTC-NCI criterion . Efficiency assess accord follow criterion : 1 . Complete effect - -full disappearance tumor foci 2 . Partial effect - -reduction tumor size and/or metastatic focus le 50 % sign new neoplasms 3 . Stabilization - reduction tumor foci size le 50 % sign new neoplasms 4 . Progress - growth tumor focus therapy . In case mosaic effect , part focus progress part stable reducing , therapy continue case analyze outside context `` Response therapy ''</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Morphologically confirm glioma ( case relapse impossibility biopsy , diagnosis base radiological diagnostic method ) Refractory first follow conventional line chemo radiotherapy , removal impossible . Glioblastoma relapse least one line conventional chemo radiotherapy , removal impossible Availability HLA partially compatible relate donor Life expectancy le 3 month Absence severe decompensated organ dysfunction Informed consent patient parent Informed consent donor Failure meet one inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Glioblastoma , recurrent glioblastoma</keyword>
</DOC>